Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET tracer aims to spot Parkinson's protein in living brains

NCT ID NCT07348250

Diagnosis Sponsor: Invicro Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This early-phase study tests a new imaging drug called [18F]MK-0947 that works with PET scans to show where a protein called α-synuclein builds up in the brain—a hallmark of Parkinson's disease. Researchers will check safety and how well the tracer works in 22 adults (some with Parkinson's, some healthy). If successful, this could lead to better tools for diagnosing and tracking Parkinson's.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
[18F]MK-0947 (a radioactive imaging drug for PET scans)
What this could lead to
If successful, this could lead to a new way to see Parkinson's-related protein buildup in the brain, helping doctors diagnose the disease earlier and track its progression.
What could go wrong
This is a very early, small study (22 people) focused on safety and imaging, not treatment. The tracer may not work as hoped, and results may not apply to all Parkinson's patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

16 people

The number who actually took part.

Started

Dec 2025

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent prior to any study procedures * Women of childbearing potential: abstinent or use 2 contraception methods (one barrier) during study and 90 days post last injection * Men: use 2 contraception methods and refrain from sperm donation during study and 90 days post last injection * PD \& HE participants: Age 40-80 years; HP participants: Age 18-50 years * Adequate circulation and normal clotting for arterial cannulation (if applicable) * HE participants: no neurological disorder, no first-degree relative with idiopathic PD * HP participants: healthy with no clinically relevant findings Exclusion Criteria: * Unwilling or unable to provide informed consent * Clinically significant hepatic, renal, cardiovascular, pulmonary, or systemic illness * Pregnant or breastfeeding * Contraindication to PET or MRI procedures (e.g., implants, claustrophobia) * History of severe allergic reactions to PET tracers or related compounds * Current or prior participation in investigational drug study within 30 days * Any condition that may interfere with study conduct or participant safety

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 Nerve Degeneration Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease Parkinson's disease (disorder) Parkinson's disease (PD)

Contacts and locations

Locations

  • Invicro (dba Perceptive)

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.